Mural Oncology (NASDAQ:MURA – Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($2.01) EPS for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05), RTT News reports.
Mural Oncology Trading Up 4.7 %
NASDAQ MURA traded up $0.17 during trading hours on Tuesday, hitting $3.80. 146,728 shares of the company’s stock were exchanged, compared to its average volume of 162,217. The stock has a 50-day simple moving average of $3.83 and a 200 day simple moving average of $3.58. The firm has a market cap of $64.68 million, a price-to-earnings ratio of -0.42 and a beta of 3.66. Mural Oncology has a 1-year low of $2.87 and a 1-year high of $5.46.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Mural Oncology in a report on Monday, November 11th.
Mural Oncology Company Profile
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
Featured Articles
- Five stocks we like better than Mural Oncology
- What does consumer price index measure?
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- What is the Shanghai Stock Exchange Composite Index?
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
